Tenderwize
Retour à la recherche

Open-house rebate agreement for Naproxen/Esomeprazole

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Aug 31, 2027 · 368 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Naproxen/Esomeprazol (ATC-Code nach WHO: M01AE52)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive rebate agreement for pharmaceutical products containing Naproxen/Esomeprazole (ATC M01AE52).
  • Open-House model: contract conclusion is open to all interested pharmaceutical companies that meet and accept the participation conditions.
Afficher le résumé complet

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Naproxen/Esomeprazole (ATC M01AE52) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. The contract term ends no later than 31.08.2027. Participation documents are available via DTVP, but the extracted procurement documents were not provided, so document-specific requirements could not be fully analyzed.

Risques

The structured data marks electronic submission as not allowed and submission method as not allowed, while the XML noti...

Key participation conditions are contained in documents not provided in the extracted text, including 'Anschreiben', 'E...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB is required.

Administrative

  • The company must meet and accept the participation conditions in the documents.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Naproxen/Esomeprazole

Single lot for a non-exclusive rebate agreement concerning the pharmaceutical product Naproxen/Esomeprazole (ATC M01AE52). Scope is supply of pharmaceutical products under an Open-House model. Place of performance is Dresden, Germany. The lot is a framework agreement/open-house style arrangement with no guaranteed minimum purchase volume and no exclusivity. Lot information comes from structured data and XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Aug 31, 2027

Détails de la procédure

Date de publication
08 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
446354-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30